English Ukrainian
Clinical medicine

EVALUATION OF ELASTOGRAPHY IN COMPARISON WITH Α2-MACROGLOBULIN, HAPTOGLOBIN, AND APOLIPOPROTEIN A1 LEVELS IN THE DIAGNOSIS OF LIVER FIBROSIS IN TYPE 2 DIABETES MELLITUS

Published 2026-09-30

Authors:

Najafova V.N.
Azerbaijan Medical University image/svg+xml
https://orcid.org/0009-0004-0951-8647
Panakhova M.S.
Azerbaijan Medical University image/svg+xml
https://orcid.org/0009-0001-0271-6796
Abstract:
This study aimed to comparatively evaluate elastography and serum biomarkers (α2-macroglobulin, haptoglobin, and apolipoprotein A1 for diagnosing liver fibrosis in patients with type 2 diabetes mellitus. The study included 108 patients: 33 without evident fibrosis (F0–F1) and 75 with fibrosis of varying severity (F2–F4). Age, body mass index, disease duration, liver elastography parameters, and serum biomarker levels were assessed. Statistical analysis included the Mann–Whitney U test, Spearman correlation, ROC analysis, and canonical correlation analysis. Body mass index was significantly associated with fibrosis progression (ρ=0.360; p<0.001). Elastography parameters correlated positively with α2-macroglobulin (ρ=0.573; p<0.001) and negatively with haptoglobin (ρ=−0.281; p=0.003). Canonical analysis identified liver stiffness and body mass index as the main clinical contributors and α2-macroglobulin and haptoglobin as the principal biochemical contributors. Combining elastography, physical parameters, and serum biomarkers may improve diagnostic assessment of liver fibrosis in patients with type 2 diabetes mellitus.
Keywords:
metabolic dysfunction–associated steatotic liver disease type 2 diabetes mellitus shear wave elastography liver fibrosis serum biomarkers
References:
  1. Ayonrinde OT, Zelesco M, Welman CJ, Abbott S, Adris N. Clinical relevance of shear wave elastography compared with transient elastography and other markers of liver fibrosis. Intern Med J. 2022;52(4):640-650. doi:10.1111/imj.15603.
  2. Castera L, Garteiser P, Laouenan C, Vidal-Trécan T, Vallet-Pichard A, Manchon P, et al. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J Hepatol. 2024;81(2):195-206. doi:10.1016/j.jhep.2024.03.023.
  3. Chan WK, Petta S, Noureddin M, Goh GBB, Wong VWS. Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity. Aliment Pharmacol Ther. 2024;59(Suppl 1):S23-S40. doi:10.1111/apt.17866.
  4. Chadha N, Sterling RK. A clinical review of noninvasive tests for hepatic fibrosis. Gastroenterol Hepatol (N Y). 2024;20(6):322-329.
  5. Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, et al. Clinical interest of serum alpha-2 macroglobulin, apolipoprotein A1, and haptoglobin in patients with non-alcoholic fatty liver disease, with and without type 2 diabetes, before or during COVID-19. Biomedicines. 2022;10(3):699. doi:10.3390/biomedicines10030699.
  6. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. doi:10.1016/j.jhep.2024.04.031.
  7. Kazi IN, Kuo L, Tsai E. Noninvasive methods for assessing liver fibrosis and steatosis. Gastroenterol Hepatol (N Y). 2024;20(1):21-29.
  8. Kim MN, Han JW, An J, Kim BK, Jin YJ, Kim SS, et al. KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease. Clin Mol Hepatol. 2024;30(Suppl):S5-S105. doi:10.3350/cmh.2024.0506.
  9. Lai JCT, Liang LY, Wong GLH. Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases? Gastroenterol Rep (Oxf). 2024;12:goae024. doi:10.1093/gastro/goae024.
  10. Qafarov IA. Biostatistics. Baku; 2025. 250 p. ISBN: 978-9952-39-330-9.
  11. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003.
  12. Sanyal AJ, Castera L, Wong VWS. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21(8):2026-2039. doi:10.1016/j.cgh.2023.03.042.
  13. Tincopa MA, Loomba R. Noninvasive tests to assess fibrosis and disease severity in metabolic dysfunction-associated steatotic liver disease. Semin Liver Dis. 2024;44(3):287-299. doi:10.1055/s-0044-1788277.
  14. Tsochatzis EA. Screening for liver fibrosis-sequential non-invasive testing works best. J Hepatol. 2023;79(2):263-265. doi:10.1016/j.jhep.2023.05.024.
  15. Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010.e8. doi:10.1016/j.cgh.2024.03.006.
  16. Zhang YN, Fowler KJ, Ozturk A, Potu CK, Louie AL, Montes V, et al. Liver fibrosis imaging: a clinical review of ultrasound and magnetic resonance elastography. J Magn Reson Imaging. 2020;51(1):25-42. doi:10.1002/jmri.26716.
Publication:
«World of Medicine and Biology» Vol. 22 No. 97 (2026), pp. 124-129
UDC 616.36-004-073.43:616.379-008.64
DOI:
https://doi.org/10.26724/2079-8334-2026-3-97-124-129